Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
- Status
- COMPLETED
- Phase
- PHASE1
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
- Status
- COMPLETED
- Phase
- PHASE2
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2